Clinical Trials Browser

Phase 1 × Carcinoma × Sorafenib × Clear all

NCT02323906 2017-03-20

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

Phase 1 Terminated

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms

NCT00941863 2016-03-22

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Phase 1 Completed

158 enrolled 17 charts

Carcinoma